TABLE 2.
Human plasma LMs from patients with CAD
| LM | Q1 | Q3 | CAD | CAD + Lovaza |
|---|---|---|---|---|
| DHA bioactive metabolome | ||||
| RvD1 | 375 | 215 | — | — |
| RvD2 | 375 | 215 | — | — |
| RvD3 | 375 | 181 | — | — |
| RvD5 | 359 | 199 | — | — |
| RvD6 | 359 | 159 | 11.0 ± 3.4 | 22.5 ± 4.6 |
| AT-RvD1 | 375 | 141 | 14.6 ± 2.7 | 12.9 ± 2.6 |
| AT-RvD3 | 375 | 181 | — | 7.1 ± 3.7 |
| PD1 | 359 | 153 | — | — |
| AT-PD1 | 359 | 153 | 3.0 ± 0.5 | 6.0 ± 1.9 |
| MaR1 | 359 | 250 | — | — |
| EPA bioactive metabolome | ||||
| RvE1 | 349 | 161 | — | — |
| RvE2 | 333 | 115 | 8.2 ± 8.2 | 44.8 ± 38.6 |
| RvE3 | 333 | 201 | 69.0 ± 11.6 | 61.7 ± 2.8 |
| Arachidonic acid bioactive metabolome | ||||
| LXA4 | 351 | 115 | — | — |
| LXB4 | 351 | 115 | 453.9 ± 88.4 | 369.3 ± 105.2 |
| 5S,15S-diHETE | 335 | 235 | 45.0 ± 4.1 | 48.2 ± 10.5 |
| AT-LXA4 | 351 | 115 | — | — |
| AT-LXB4 | 351 | 221 | — | 20.5 ± 4.3 |
| LTB4 | 335 | 195 | — | — |
| PGD2 | 351 | 189 | 1.7 ± 0.2 | 0.9 ± 0.5 |
| PGE2 | 351 | 189 | 3.1 ± 0.3 | 1.7 ± 0.9 |
| PGF2α | 353 | 193 | 3.1 ± 0.7 | 1.0 ± 0.5 |
| TxB2 | 369 | 169 | 3.2 ± 1.6 | 2.1 ± 1.4 |
Results are expressed as picograms per milliliter; means ± sem; n = 3. Limit of detection, ∼0.1 pg. Human plasma from patients with CAD who received aspirin or aspirin and Lovaza (3360 mg EPA and DHA daily for 1 yr) were extracted, and LM levels were investigated by LM metabololipidomics (see Materials and Methods for details). 5S,15S-diHETE, 5S,15S‐dihydroxy‐eicosatetraenoic acid; LTB4, leukotriene B4; TxB2, thromboxane B2; Q1, M-H (parent ion); Q3, diagnostic ion in the MS-MS (daughter ion). LMs with no CAD value are below the limit of detection. Those SPMs absent in patients with CAD who did not receive Lovaza were present in healthy volunteers from a prior study that used analysis conditions identical to those of the current report, with the exception of PD1, MaR1, LXA4, and AT-LXA4, which were absent in both healthy volunteers and patients with CAD (21).